Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

W See; P Iversen; M Wirth; D McLeod; L Garside; T Morris

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

W See, P Iversen, M Wirth, D McLeod, L Garside, T Morris

32 Citations (Scopus)

Abstract

To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.

Original language	English
Journal	European Urology
Volume	44
Issue number	5
Pages (from-to)	512-7; discussion 517-8
ISSN	0302-2838
Publication status	Published - 2003

Keywords

Adult
Aged
Aged, 80 and over
Androgen Antagonists
Anilides
Chemotherapy, Adjuvant
Disease Progression
Double-Blind Method
Humans
Male
Middle Aged
Neoplasm Staging
Nitriles
Proportional Hazards Models
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Risk Factors
Survival Analysis
Tosyl Compounds

Cite this

@article{fc07b6bcfef546a99c5ad97940733230,

title = "Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer",

abstract = "To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.",

keywords = "Adult, Aged, Aged, 80 and over, Androgen Antagonists, Anilides, Chemotherapy, Adjuvant, Disease Progression, Double-Blind Method, Humans, Male, Middle Aged, Neoplasm Staging, Nitriles, Proportional Hazards Models, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk Factors, Survival Analysis, Tosyl Compounds",

author = "W See and P Iversen and M Wirth and D McLeod and L Garside and T Morris",

year = "2003",

language = "English",

volume = "44",

pages = "512--7; discussion 517--8",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

AU - See, W

AU - Iversen, P

AU - Wirth, M

AU - McLeod, D

AU - Garside, L

AU - Morris, T

PY - 2003

Y1 - 2003

N2 - To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.

AB - To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Androgen Antagonists

KW - Anilides

KW - Chemotherapy, Adjuvant

KW - Disease Progression

KW - Double-Blind Method

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Nitriles

KW - Proportional Hazards Models

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Risk Factors

KW - Survival Analysis

KW - Tosyl Compounds

UR - https://www.scopus.com/pages/publications/0142228732

M3 - Journal article

C2 - 14572747

SN - 0302-2838

VL - 44

SP - 512-7; discussion 517-8

JO - European Urology

JF - European Urology

IS - 5

ER -

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

Abstract

Keywords

Other files and links

Fingerprint

Cite this